Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Intrinsic Value
Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. [ Read More ]
The intrinsic value of one
SUNPHARMA
stock under the Base Case scenario is
927.45
INR.
Compared to the current market price of 1 525.05 INR,
Sun Pharmaceutical Industries Ltd
is
Overvalued by 39%.
Sun Pharmaceutical Industries Ltd's market capitalization is 3.7T INR.
SUNPHARMA stock price is 1 525.05 INR.
SUNPHARMA stock (927.45 INR) is 39% less than its price (1525.05 INR).
SUNPHARMA stock (630.12 INR) is 59% less than its price (1525.05 INR). Open DCF Valuation
SUNPHARMA stock (1 224.78 INR) is 20% less than its price (1525.05 INR). Open Relative Valuation
SUNPHARMA has upside potential of 1% compared to the average analyst price target.
Open Wall St Estimates
SUNPHARMA has positive three-year average ROE (Return on Equity): 11%. The company is efficient at transforming stockholders' equity into net income.
SUNPHARMA's Revenue has grown by 12% over the past 12 months.
SUNPHARMA has positive Net Income for the last twelve months.
SUNPHARMA's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 15%.
SUNPHARMA's ROE (Return on Equity) for the past 12 months is positive and is equal to 16%.
SUNPHARMA has positive three-year average ROIC (Return on Invested Capital): 13%. The company is efficient at using invested capital to generate operating income.
SUNPHARMA's ROIC (Return on Invested Capital) has increased in the last 3 years from 10% to 15%.
SUNPHARMA's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
SUNPHARMA's ROE (Return on Equity) has increased in the last 3 years from 6% to 16%.
SUNPHARMA has positive Operating Income for the last twelve months.
SUNPHARMA's Revenue has been growing by 13% per year for the last 3 years.
SUNPHARMA has positive Free Cash Flow for the last twelve months.
SUNPHARMA's short-term assets (393B INR) exceed its short-term liabilties (150B INR).
SUNPHARMA has positive Gross Profit for the last twelve months.
SUNPHARMA's D/E (Debt to Equity) is very low and is equal to 0.01.
SUNPHARMA's long-term assets (794B INR) exceed its long-term liabilties (196B INR).
SUNPHARMA has negative Net Debt. This means that the company has more cash and short-term investments (158B INR) than debt (3B INR).
SUNPHARMA's Altman Z-Score is very high and is equal to 11.44.
SUNPHARMA earns more than enough operating income (101B INR) to safely cover interest payments on its debt (2B INR).
Valuation Backtest
Sun Pharmaceutical Industries Ltd
Run backtest to discover the historical profit from buying and selling
SUNPHARMA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Sun Pharmaceutical Industries Ltd
Balance Sheet Decomposition
Sun Pharmaceutical Industries Ltd
| Current Assets | 393.3B |
| Cash & Short-Term Investments | 157.7B |
| Receivables | 113.5B |
| Other Current Assets | 122.2B |
| Non-Current Assets | 401.1B |
| Long-Term Investments | 53.8B |
| PP&E | 111.2B |
| Intangibles | 177.9B |
| Other Non-Current Assets | 58.2B |
| Current Liabilities | 150.2B |
| Accounts Payable | 57B |
| Other Current Liabilities | 93.2B |
| Non-Current Liabilities | 45.9B |
| Long-Term Debt | 3.1B |
| Other Non-Current Liabilities | 42.8B |
Earnings Waterfall
Sun Pharmaceutical Industries Ltd
|
Revenue
|
474.4B
INR
|
|
Cost of Revenue
|
-105.3B
INR
|
|
Gross Profit
|
369.1B
INR
|
|
Operating Expenses
|
-267.7B
INR
|
|
Operating Income
|
101.5B
INR
|
|
Other Expenses
|
-12.4B
INR
|
|
Net Income
|
89.1B
INR
|
Free Cash Flow Analysis
Sun Pharmaceutical Industries Ltd
SUNPHARMA Profitability Score
Profitability Due Diligence
Sun Pharmaceutical Industries Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Sun Pharmaceutical Industries Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
SUNPHARMA Solvency Score
Solvency Due Diligence
Sun Pharmaceutical Industries Ltd's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Score
Sun Pharmaceutical Industries Ltd's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SUNPHARMA Price Targets Summary
Sun Pharmaceutical Industries Ltd
According to Wall Street analysts, the average 1-year price target for
SUNPHARMA
is 1 534.17 INR
with a low forecast of 1 151.4 INR and a high forecast of 1 963.5 INR.
Shareholder Return
SUNPHARMA Price
Sun Pharmaceutical Industries Ltd
| Average Annual Return | 26.74% |
| Standard Deviation of Annual Returns | 18.14% |
| Max Drawdown | -29% |
| Market Capitalization | 3.7T INR |
| Shares Outstanding | 2 403 571 429 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Sun Pharmaceutical Industries Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of manufacturing, developing and marketing a range of generic formulations. The company produces a portfolio of generic and specialty medicines targeting a spectrum of chronic and acute treatments. The Company’s product portfolio includes generics, branded generics, specialty, over the counter (OTC)/consumer healthcare products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and intermediates. Its OTC brands includes Faringosept , Revital, and Volini. The firm offers its products in variety of dosage forms, such as tablets, capsules, sprays, injectables, inhalers, ointments, creams and liquids. Its portfolio of specialty products, branded generics are available across 100 countries. The firm operates manufacturing sites across 6 continents.
Contact
IPO
Employees
Officers
The intrinsic value of one
SUNPHARMA
stock under the Base Case scenario is
927.45
INR.
Compared to the current market price of 1 525.05 INR,
Sun Pharmaceutical Industries Ltd
is
Overvalued by 39%.
You don't have any saved screeners yet
